About: Impact of hospitalised patients with COVID-19 taking Renin-Angiotensin-Aldosterone System inhibitors: a systematic review and meta-analysis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Impact of hospitalised patients with COVID-19 taking Renin-Angiotensin-Aldosterone System inhibitors: a systematic review and meta-analysis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Impact of hospitalised patients with COVID-19 taking Renin-Angiotensin-Aldosterone System inhibitors: a systematic review and meta-analysis
Creator	Baral, Ranu Vassiliou, Vassilios Ma, Vassiliou Vassilios, Prof White, Maddie
source	MedRxiv
abstract	Inhibitors of the Renin-Angiotensin-Aldosterone System (RAAS) notably Angiotensin-Converting Enzyme inhibitors (ACEi) or Angiotensin Receptor Blockers (ARB) have been scrutinised in hypertensive patients hospitalised with coronavirus disease 2019 (COVID-19) following some initial data they might adversely affect prognosis. With an increasing number of COVID-19 cases worldwide and the likelihood of a second wave of infection it is imperative to better understand the impact RAAS inhibitor use in antihypertensive covid positive hospitalised patients. A systematic review and meta-analysis of ACEi or ARB in patients admitted with COVID-19 was conducted. PubMed and Embase were searched and six studies were included in the meta-analysis. Pooled analysis demonstrated that 18.3% of the patients admitted with COVID-19 were prescribed ACEi/ARBs (0.183, CI 0.129 to 0.238, p<0.001). The use of RAAS inhibitors did not show any association with critical events (Pooled OR 0.833 CI 0.605 to 1.148, p=0.264) or death (Pooled OR 0.650, CI 0.356 to 1.187, p=0.161). In conclusion, our meta-analysis including critical events and mortality data on patients prescribed ACEi/ARB and hospitalised with COVID-19, found no evidence to associate ACEi/ARB with death or adverse events.
has issue date	2020-05-08(xsd:dateTime)
bibo:doi	10.1101/2020.05.03.20089375
has license	medrxiv
sha1sum (hex)	49a1711050bffdefa9401306ef6ef5c837b18137
schema:url	https://doi.org/10.1101/2020.05.03.20089375
resource representing a document's title	Impact of hospitalised patients with COVID-19 taking Renin-Angiotensin-Aldosterone System inhibitors: a systematic review and meta-analysis
resource representing a document's body	covid:49a1711050bffdefa9401306ef6ef5c837b18137#body_text
is schema:about of	named entity 'COVID-19' named entity 'conducted' named entity 'ACEi' named entity 'meta-analysis' named entity 'inhibitors' named entity 'System' named entity 'Angiotensin' named entity 'critical' named entity 'demonstrated' named entity 'studies' named entity 'inhibitor' named entity 'ARBs' named entity 'meta-analysis' named entity 'imperative' named entity 'adverse events' named entity 'ACEi' named entity 'COVID' named entity 'Angiotensin-Converting Enzyme inhibitors' named entity 'meta-analysis' named entity 'coronavirus disease 2019' named entity 'Renin-Angiotensin-Aldosterone' named entity 'systematic review' named entity 'antihypertensive' named entity 'RAAS' named entity 'severe acute respiratory syndrome coronavirus 2' named entity 'medRxiv' named entity 'preprint' named entity 'meta-analysis' named entity 'ACEi' named entity 'preprint' named entity 'COVID' named entity 'peer review' named entity 'hypertensive' named entity 'peer review' named entity 'ARB' named entity 'systematic review' named entity 'Angiotensin-Converting Enzyme inhibitors' named entity 'COVID' named entity 'Angiotensin Receptor Blockers' named entity 'meta-analysis' named entity 'Meta-Analyses' named entity 'meta-analysis' named entity 'COVID' named entity 'systematic review' named entity 'COVID' named entity 'adult respiratory distress syndrome' named entity 'medRxiv' named entity 'infection' named entity 'ARB' named entity 'systematic review' named entity 'ACEi' named entity 'ACEi' named entity 'preprint' named entity 'SARS-COV-2' named entity 'RAAS' named entity 'meta-analysis' named entity 'ACEi' named entity 'medRxiv' named entity 'non-invasive ventilation' named entity 'medRxiv' named entity 'ACEi' named entity 'random effects' named entity 'ACE2' named entity 'ARB' named entity 'cardiovascular diseases' named entity 'cardiovascular diseases' named entity 'RAAS' named entity 'receptor' named entity 'meta-analysis' named entity 'RAAS' named entity 'COVID' named entity 'COVID-19' named entity 'Angiotensin-Converting Enzyme inhibitors' named entity 'ARDS' named entity 'antihypertensives' named entity 'ARB' named entity 'acute lung injury' named entity '95% CI' named entity 'systematic review' named entity 'RAAS' named entity 'Covid'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software